- Home
- GENK vs CTXR Comparison
GENK vs CTXR Comparison
Compare GENK & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- CTXR
- Stock Information
- Founded
- GENK 2011
- CTXR 2007
- Country
- GENK United States
- CTXR United States
- Employees
- GENK N/A
- CTXR N/A
- Industry
- GENK Restaurants
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- CTXR Health Care
- Exchange
- GENK Nasdaq
- CTXR Nasdaq
- Market Cap
- GENK 20.4M
- CTXR 23.0M
- IPO Year
- GENK 2023
- CTXR N/A
- Fundamental
- Price
- GENK $3.14
- CTXR $1.13
- Analyst Decision
- GENK Strong Buy
- CTXR Strong Buy
- Analyst Count
- GENK 2
- CTXR 3
- Target Price
- GENK $7.00
- CTXR $53.00
- AVG Volume (30 Days)
- GENK 73.2K
- CTXR 453.7K
- Earning Date
- GENK 08-06-2025
- CTXR 08-12-2025
- Dividend Yield
- GENK 3.81%
- CTXR N/A
- EPS Growth
- GENK N/A
- CTXR N/A
- EPS
- GENK N/A
- CTXR N/A
- Revenue
- GENK $216,137,000.00
- CTXR N/A
- Revenue This Year
- GENK $12.35
- CTXR N/A
- Revenue Next Year
- GENK $14.62
- CTXR $851.67
- P/E Ratio
- GENK N/A
- CTXR N/A
- Revenue Growth
- GENK 10.67
- CTXR N/A
- 52 Week Low
- GENK $3.13
- CTXR $0.65
- 52 Week High
- GENK $10.33
- CTXR $15.25
- Technical
- Relative Strength Index (RSI)
- GENK 37.18
- CTXR 40.37
- Support Level
- GENK $3.13
- CTXR $1.23
- Resistance Level
- GENK $3.39
- CTXR $1.57
- Average True Range (ATR)
- GENK 0.14
- CTXR 0.11
- MACD
- GENK 0.00
- CTXR -0.00
- Stochastic Oscillator
- GENK 10.58
- CTXR 4.76
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.